Market
Scenario
Encephalomyelitis is brain or spinal cord inflammation caused due to
virus, infections, and other foreign particles. The patient suffering from
autoimmune diseases and AIDS are more prone to the diseases. A wide range of
drugs are available for the treatment of this disease, however no precise
treatment is available to cure the disease. Increasing prevalence of
encephalomyelitis and autoimmune diseases has boosted the growth of the market.
According to the WHO, 4.3 million people across the globe are affected by this
disease. Additionally, changing lifestyle, increasing geriatric population,
increasing need for better treatment has driven the global market. Moreover,
increasing government support along with the per capita income have fuelled the
market growth. However, limited and high cost of treatment options may retard
the growth of the market over the assessment period.
The
global encephalomyelitis market is expected to grow at a CAGR of ~8.1 %
during the forecast period 2017-2023.
Segmentations
The
global encephalomyelitis market is segmented on the basis of types, treatment
and end users.
On the
basis of types, the market is segmented into acute disseminated
encephalomyelitis, encephalomyelitis disseminata, antiMOG associated
encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and
others.
On the
basis of treatment, the market is segmented into drug treatment,
plasmapheresis, surgery, and others. Drug therapy is further segmented into
antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood
stabilizers, and others.
On the
basis of end users, the market is segmented into hospital, clinics and others.
Regional
Analysis
The
Americas command a major share of the market owing to the large patient
population, growing prevalence of encephalomyelitis & autoimmune diseases,
and strong government support for research & development. According to the
American Autoimmune Related Diseases Association, approximately 50 million
people in the U.S. were reported to be suffering from autoimmune diseases in
2014.
Europe
accounts for the second largest market across the globe, which is followed by
Asia Pacific. Strong government support, availability of funds for research and
high healthcare expenditure drives the growth of the market. Asia Pacific is
the fastest growing market. China, and India are the key contributors to the
market growth due to presence of huge population base, increasing prevalence of
AIDS and autoimmune diseases, rapidly growing economy, and increasing
healthcare expenditure. Additionally, increasing government support, and presence
of huge opportunity have fuelled the growth of the market in Asia Pacific.
The
Middle East & Africa holds the least share of the global market due to
limited availability of medical facilities and poor economic condition in
African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the
Middle East & African market owing to the well-developed economy and high
healthcare spending.
Key
Players
Some of
key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi
(France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.),
Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis
AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and
Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie
Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc.
(U.S.), and Oncomed Pharmaceuticals (U.S.).
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1
Definition
2.2
Scope Of The Study
2.2.1
Research Objective
2.2.2
Assumptions
2.2.3
Limitations
Chapter 3. Research Methodology
3.1
Introduction
3.2
Primary Research
3.3
Secondary Research
3.4
Market Size Estimation
Chapter 4. Market Dynamics
4.1
Drivers
4.2
Restrains
4.3
Opportunities
4.4
Challenges
4.5
Macroeconomic Indicators
4.6
Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1
Porter’s Five Forces Analysis
5.1.1
Bargaining Power Of Suppliers
5.1.2
Bargaining Power Of Buyers
5.1.3
Threat Of New Entrants
5.1.4
Threat Of Substitutes
5.1.5
Intensity Of Rivalry
...Continued
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment